Skip to main content
Erschienen in: Gastric Cancer 2/2018

01.03.2018 | Original Article

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?

verfasst von: Susanne Blank, Thomas Schmidt, Patrick Heger, Moritz J. Strowitzki, Leila Sisic, Ulrike Heger, Henrik Nienhueser, Georg Martin Haag, Thomas Bruckner, André L. Mihaljevic, Katja Ott, Markus W. Büchler, Alexis Ulrich

Erschienen in: Gastric Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The optimal surgical approach for adenocarcinoma directly at the esophagogastric junction (AEG II) is still under debate. This study aims to evaluate the differences between right thoracoabdominal esophagectomy (TAE) (Ivor–Lewis operation) and transhiatal extended gastrectomy (THG) for AEG II.

Methods

From a prospective database, 242 patients with AEG II (TAE, n = 56; THG, n = 186) were included and analyzed according to characteristics and perioperative morbidity and mortality and overall survival (chi-square, Mann–Whitney U, log-rank, Cox regression).

Results

Groups were comparable at baseline with exception of age. Patients older than 70 years were more frequently resected by THG (p = 0.003). No differences in perioperative morbidity (p = 0.197) and mortality (p = 0.711) were observed, including anastomotic leakages (p = 0.625) and pulmonary complications (p = 0.494). There was no significant difference in R0 resection (p = 0.719) and number of resected lymph nodes (p = 0.202). Overall median survival was 38.4 months. Survival after TAE was significantly longer than after THG (median OS not reached versus 33.6 months, p = 0.02). Multivariate analysis revealed pN-category (p < 0.001) and type of surgery (p = 0.017) as independent prognostic factors. The type of surgery was confirmed as prognostic factor in locally advanced AEG II (cT 3/4 or cN1), but not in cT1/2 and cN0 patients.

Conclusions

Our single-center experience suggests that patients with (locally advanced) AEG II tumors may benefit from TAE compared to THG. For further evaluation, a randomized trial would be necessary.
Literatur
1.
Zurück zum Zitat Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9 (Epub 1991/03/23).CrossRefPubMed Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9 (Epub 1991/03/23).CrossRefPubMed
2.
4.
Zurück zum Zitat Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13(2):63–73.CrossRefPubMed Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer. 2010;13(2):63–73.CrossRefPubMed
5.
Zurück zum Zitat Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut. 2008;57(3):298–305. doi:10.1136/gut.2007.137364 (Epub 2007/10/30).CrossRefPubMed Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut. 2008;57(3):298–305. doi:10.​1136/​gut.​2007.​137364 (Epub 2007/10/30).CrossRefPubMed
6.
7.
Zurück zum Zitat Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19(2):677–83. doi:10.1245/s10434-011-1983-x (Epub 2011/08/09).CrossRefPubMed Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19(2):677–83. doi:10.​1245/​s10434-011-1983-x (Epub 2011/08/09).CrossRefPubMed
8.
Zurück zum Zitat Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353–60.CrossRef Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232(3):353–60.CrossRef
9.
Zurück zum Zitat von Rahden BH, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol. 2006;12(41):6608–13 (Epub 2006/11/01).CrossRef von Rahden BH, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol. 2006;12(41):6608–13 (Epub 2006/11/01).CrossRef
10.
Zurück zum Zitat Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, et al. Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol. 2009;16(2):304–10. doi:10.1245/s10434-008-0247-x.CrossRefPubMed Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, et al. Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol. 2009;16(2):304–10. doi:10.​1245/​s10434-008-0247-x.CrossRefPubMed
12.
16.
Zurück zum Zitat Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg. 2008;95(1):80–4. doi:10.1002/bjs.5912.CrossRefPubMed Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg. 2008;95(1):80–4. doi:10.​1002/​bjs.​5912.CrossRefPubMed
17.
Zurück zum Zitat Fuchs H, Holscher AH, Leers J, Bludau M, Brinkmann S, Schroder W, et al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer. 2016;19(1):312–7. doi:10.1007/s10120-015-0466-3.CrossRefPubMed Fuchs H, Holscher AH, Leers J, Bludau M, Brinkmann S, Schroder W, et al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer. 2016;19(1):312–7. doi:10.​1007/​s10120-015-0466-3.CrossRefPubMed
18.
Zurück zum Zitat Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.CrossRefPubMed Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.​1056/​NEJMoa055531.CrossRefPubMed
19.
Zurück zum Zitat Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. doi:10.1200/JCO.2010.33.0597.CrossRefPubMed Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. doi:10.​1200/​JCO.​2010.​33.​0597.CrossRefPubMed
20.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi:10.1016/S1470-2045(11)70142-5.CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi:10.​1016/​S1470-2045(11)70142-5.CrossRefPubMed
21.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6. doi:10.1200/JCO.2008.17.0506.CrossRefPubMed Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6. doi:10.​1200/​JCO.​2008.​17.​0506.CrossRefPubMed
22.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. doi:10.1056/NEJMoa1112088.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. doi:10.​1056/​NEJMoa1112088.CrossRefPubMed
23.
Zurück zum Zitat Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–7. doi:10.1093/annonc/mdw010 (Epub 2016/01/20).CrossRefPubMed Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–7. doi:10.​1093/​annonc/​mdw010 (Epub 2016/01/20).CrossRefPubMed
24.
Zurück zum Zitat Ott K, Bader F, Lordick F, Feith M, Bartels H, Siewert J. Surgical factors influence the outcome after Ivor–Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol. 2009;16(4):1017–25. doi:10.1245/s10434-009-0336-5.CrossRefPubMed Ott K, Bader F, Lordick F, Feith M, Bartels H, Siewert J. Surgical factors influence the outcome after Ivor–Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol. 2009;16(4):1017–25. doi:10.​1245/​s10434-009-0336-5.CrossRefPubMed
25.
Zurück zum Zitat Kirschner MB. Ein neues Verfahren der Oesophagoplastik. Arch Klin Chir. 1920;114:604–12. Kirschner MB. Ein neues Verfahren der Oesophagoplastik. Arch Klin Chir. 1920;114:604–12.
26.
Zurück zum Zitat Akiyama H, Hiyama M, Hashimoto C. Resection and reconstruction for carcinoma of the thoracic oesophagus. Br J Surg. 1976;63(3):206–9.CrossRefPubMed Akiyama H, Hiyama M, Hashimoto C. Resection and reconstruction for carcinoma of the thoracic oesophagus. Br J Surg. 1976;63(3):206–9.CrossRefPubMed
27.
Zurück zum Zitat Hartwig W, Strobel O, Schneider L, Hackert T, Hesse C, Buchler MW, et al. Fundus rotation gastroplasty vs. Kirschner–Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results. World J Surg. 2008;32(8):1695–702. doi:10.1007/s00268-008-9648-z (Epub 2008/06/17).CrossRefPubMed Hartwig W, Strobel O, Schneider L, Hackert T, Hesse C, Buchler MW, et al. Fundus rotation gastroplasty vs. Kirschner–Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results. World J Surg. 2008;32(8):1695–702. doi:10.​1007/​s00268-008-9648-z (Epub 2008/06/17).CrossRefPubMed
28.
Zurück zum Zitat Buchler MW, Baer HU, Seiler C, Schilling M. A technique for gastroplasty as a substitute for the esophagus: fundus rotation gastroplasty. J Am Coll Surg. 1996;182(3):241–5 (Epub 1996/03/01).PubMed Buchler MW, Baer HU, Seiler C, Schilling M. A technique for gastroplasty as a substitute for the esophagus: fundus rotation gastroplasty. J Am Coll Surg. 1996;182(3):241–5 (Epub 1996/03/01).PubMed
29.
Zurück zum Zitat Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18(3):550–63. doi:10.1007/s10120-014-0403-x (Epub 2014/09/07).CrossRefPubMed Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18(3):550–63. doi:10.​1007/​s10120-014-0403-x (Epub 2014/09/07).CrossRefPubMed
30.
Zurück zum Zitat Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934–9. doi:10.1097/SLA.0b013e318216f449 (Epub 2011/04/15).CrossRefPubMed Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934–9. doi:10.​1097/​SLA.​0b013e318216f449​ (Epub 2011/04/15).CrossRefPubMed
31.
Zurück zum Zitat Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer (Phila). 2003;98(7):1521–30. doi:10.1002/cncr.11660.CrossRef Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer (Phila). 2003;98(7):1521–30. doi:10.​1002/​cncr.​11660.CrossRef
33.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, et al. Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–7. doi:10.1016/j.ejso.2015.05.005.CrossRefPubMed Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, et al. Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol. 2015;41(10):1340–7. doi:10.​1016/​j.​ejso.​2015.​05.​005.CrossRefPubMed
36.
Zurück zum Zitat Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich MF, Marx A, et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg. 2012;99(10):1406–14. doi:10.1002/bjs.8884 (Epub 2012/09/11).CrossRefPubMed Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich MF, Marx A, et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg. 2012;99(10):1406–14. doi:10.​1002/​bjs.​8884 (Epub 2012/09/11).CrossRefPubMed
38.
Zurück zum Zitat Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg. 2008;32(6):1013–20. doi:10.1007/s00268-008-9470-7 (Epub 2008/02/27).CrossRefPubMed Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg. 2008;32(6):1013–20. doi:10.​1007/​s00268-008-9470-7 (Epub 2008/02/27).CrossRefPubMed
40.
41.
Zurück zum Zitat Nienhueser H, Kunzmann R, Sisic L, Blank S, Strowitzk MJ, Bruckner T, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112(4):387–95. doi:10.1002/jso.24004 (Epub 2015/08/26).CrossRefPubMed Nienhueser H, Kunzmann R, Sisic L, Blank S, Strowitzk MJ, Bruckner T, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112(4):387–95. doi:10.​1002/​jso.​24004 (Epub 2015/08/26).CrossRefPubMed
42.
Zurück zum Zitat Mariette C, Castel B, Balon JM, Van Seuningen I, Triboulet JP. Extent of oesophageal resection for adenocarcinoma of the oesophagogastric junction. Eur J Surg Oncol. 2003;29(7):588–93.CrossRefPubMed Mariette C, Castel B, Balon JM, Van Seuningen I, Triboulet JP. Extent of oesophageal resection for adenocarcinoma of the oesophagogastric junction. Eur J Surg Oncol. 2003;29(7):588–93.CrossRefPubMed
43.
Zurück zum Zitat Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007;134(2):378–85.CrossRefPubMed Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007;134(2):378–85.CrossRefPubMed
45.
Zurück zum Zitat Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R-0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240(6):962–74. doi:10.1097/01.sla.0000145925.70409.d7.CrossRefPubMedPubMedCentral Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R-0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240(6):962–74. doi:10.​1097/​01.​sla.​0000145925.​70409.​d7.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, et al. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42(4):351–8. doi:10.1007/s00595-011-0114-4.CrossRefPubMed Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, et al. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42(4):351–8. doi:10.​1007/​s00595-011-0114-4.CrossRefPubMed
47.
Zurück zum Zitat Monig SP, Baldus SE, Zirbes TK, Collet PH, Schroder W, Schneider PM, et al. Topographical distribution of lymph node metastasis in adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology. 2002;49(44):419–22.PubMed Monig SP, Baldus SE, Zirbes TK, Collet PH, Schroder W, Schneider PM, et al. Topographical distribution of lymph node metastasis in adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology. 2002;49(44):419–22.PubMed
48.
Zurück zum Zitat Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal–transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51. doi:10.1016/s1470-2045(06)70766-5.CrossRefPubMed Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal–transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51. doi:10.​1016/​s1470-2045(06)70766-5.CrossRefPubMed
49.
Zurück zum Zitat Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102(4):341–8. doi:10.1002/bjs.9764 (Epub 2015/01/22).CrossRefPubMedPubMedCentral Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102(4):341–8. doi:10.​1002/​bjs.​9764 (Epub 2015/01/22).CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100(4):456–64. doi:10.1002/bjs.9015.CrossRefPubMed Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg. 2013;100(4):456–64. doi:10.​1002/​bjs.​9015.CrossRefPubMed
52.
Zurück zum Zitat Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, et al. Long-term survival in patients with gastroesophageal junction cancer treated with preoperative therapy: do thoracic and abdominal approaches differ? Ann Surg Oncol. 2016;23(2):626–32. doi:10.1245/s10434-015-4898-0.CrossRefPubMed Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, Elimova E, et al. Long-term survival in patients with gastroesophageal junction cancer treated with preoperative therapy: do thoracic and abdominal approaches differ? Ann Surg Oncol. 2016;23(2):626–32. doi:10.​1245/​s10434-015-4898-0.CrossRefPubMed
54.
Zurück zum Zitat Palazzo F, Rosato EL, Chaudhary A, Evans NR 3rd, Sendecki JA, Keith S, et al. Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction. J Am Coll Surg. 2015;220(4):672–9. doi:10.1016/j.jamcollsurg.2014.12.023.CrossRefPubMed Palazzo F, Rosato EL, Chaudhary A, Evans NR 3rd, Sendecki JA, Keith S, et al. Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction. J Am Coll Surg. 2015;220(4):672–9. doi:10.​1016/​j.​jamcollsurg.​2014.​12.​023.CrossRefPubMed
Metadaten
Titel
Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?
verfasst von
Susanne Blank
Thomas Schmidt
Patrick Heger
Moritz J. Strowitzki
Leila Sisic
Ulrike Heger
Henrik Nienhueser
Georg Martin Haag
Thomas Bruckner
André L. Mihaljevic
Katja Ott
Markus W. Büchler
Alexis Ulrich
Publikationsdatum
01.03.2018
Verlag
Springer Japan
Erschienen in
Gastric Cancer / Ausgabe 2/2018
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-017-0746-1

Weitere Artikel der Ausgabe 2/2018

Gastric Cancer 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.